- Oct 19
Second Dose of Palonosetron Reduces CINV in Pediatric Cancer Patients
An additional dose of palonosetron can help prevent chemotherapy-induced nausea and vomiting (CINV) in children with cancer who are...
- Sep 13
Breakthrough as new drug promises to shield child cancer patients from hearing loss
A new study, which is to be presented to the RNID Hearing Therapeutics Summit, found that a drug called Pedmark, also known as ...
- Sep 12
Study finds higher breast cancer risk after certain forms of childhood cancer treatment
In a new study, scientists from the Princess Máxima Center investigated the risk of breast cancer in women who were treated for childhood...
- Nov 30, 2022
Common chemotherapy drug could carry toxic inheritance for future generations of cancer survivors
A common chemotherapy drug could carry a toxic inheritance for children and grandchildren of adolescent cancer survivors, Washington ...
- Oct 19, 2022
Research aims to spare children from painful adverse effects of chemotherapy
Starobova, whose research focuses on chemotherapy-induced adverse effects, received a fellowship grant from Children’s Hospital...
- Aug 3, 2021
Heated chemotherapy can help some children with cancer
Tumors that have spread to the lining of the abdomen are tough to treat. But a select number of cancer teams across the country have...
- Oct 5, 2020
Childhood chemo alters heart's caretaker cells, study finds
Cancer chemotherapy changes the function of cells that repair heart injury, researchers at The University of Texas Health Science Center...
- Nov 5, 2019
Chemotherapy sometimes set the stage for drug-resistant leukemia at relapse
An international collaboration has identified therapy-induced, drug-resistance mutations in children with acute lymphoblastic leukemia...
- Mar 16, 2018
Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
Cancer-associated cognitive impairment, commonly known as chemo brain, is an adverse effect of cancer and its treatment that survivors...
- Nov 6, 2015
End Stage Chemotherapy: A physician’s perspective
One of the hardest discussions between an oncologist and their patient occurs at the time of transition from active anti-cancer therapy...